Key Takeaway: The article discusses the identification of transmembrane protein 97 as a potential synaptic receptor for amyloid beta in Alzheimer's disease. This discovery may provide new insights into the mechanisms of Alzheimer's and open avenues for targeted therapies. The research highlights the importance of this protein in the context of neurodegeneration.
Price reaction · baseline $2.31 (2024-02-05 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
-2.6%
Market Sentiment Analysis
POSITIVE FACTORS
Identifies a new potential receptor for amyloid beta in Alzheimer's disease.
Could lead to novel therapeutic targets for Alzheimer's treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, et al.
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Acta Neuropathol
147, 32 (2024).
Frequently Asked Questions
What is transmembrane protein 97?
Transmembrane protein 97 is identified as a potential receptor for amyloid beta in Alzheimer's disease.
How does protein 97 relate to Alzheimer's disease?
It may play a significant role in synaptic interactions involving amyloid beta, impacting Alzheimer's pathology.
What are the implications of this research?
This discovery could lead to new therapeutic strategies targeting transmembrane protein 97 in Alzheimer's.